Random Posts
- Diabetic Symptoms & Signs of Diabetes in Toddlers - What to Do Next
- Gestational Diabetes Fear For Moms
- Healthy Diabetic Recipes - Ways to Find Make Your Favorite Recipes Diabetic Friendly
- Nailing the Normal Range - Blood Sugar Strategies For Controlling Your Glucose
- Plan 200 Calorie Diabetic Meal Plans With the Help of a List of Foods For Diabetics to Eat
- Type 2 Diabetes Diet - To Eat Carbohydrates Or Not? That is the Question
- Diabetes (Type 2) On the Increase in Australia and World Wide - What to Do?
- Diabetes Risk Factors
Prescription Diabetes Drugs
Posted by admin in Prescription Diabetes Drugs on September 11th, 2009
Combining pioglitazone with lifestyle modification does not enhance the efficacy of lifestyle modification alone for preventing Type 2 diabetes in Asian Indians with impaired glucose tolerance (IGT), show results from IDDP-2.
The thiazolidinediones have demonstrated efficacy for the primary prevention of diabetes in certain populations with IGT.
Ambady Ramachandran and colleagues (India Diabetes Research Foundation, Egmore, Chennai) have investigated whether combining pioglitazone with lifestyle modification would enhance the proven efficacy of lifestyle modification in preventing progression from IGT to Type 2 diabetes in Asian Indians, a population with several peculiarities in the clinical profile of diabetes.
As part of the Indian Diabetes Prevention Programme-2 (IDPP-2), 407 individuals with IGT received lifestyle modification plus pioglitazone 30 mg/day, or lifestyle modification plus placebo for 3 years. The primary outcome was development of Type 2 diabetes.
Writing in the journal Diabetologia, the authors report that pioglitazone did not enhance the effectiveness of lifestyle modification at reducing the number of Asian Indians with IGT who subsequently developed Type 2 diabetes.
The cumulative incidence of diabetes was 29.8% with pioglitazone and 31.6% with placebo (hazard ratio=1.084), a nonsignificant difference. Normoglycemia was achieved in 40.9% and 32.3% of participants receiving pioglitazone and placebo, respectively.
Although these results are at odds with studies such as ACT NOW (Actos Now for Prevention of Diabetes), which have shown a significant benefit for pioglitazone in reducing conversion of IGT to diabetes in a US population, they are in agreement with the results of IDDP-1, which showed that combining metformin and lifestyle modification did not have an added benefit.
The results of IDDP-2 have led the authors to suggest that pioglitazone does not reduce blood glucose in non-diabetic Asian Indians, but does reduce it in diabetic patients.
“It is probable that the lack of efficacy of pioglitazone noted in the present study may reflect an ethnic variation, which may relate to the differences in mechanisms of insulin resistance,” they conclude.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009
- Juvenile Diabetes Symptoms
- When Diabetes Attacks Kids
- 7 Fruits For Diabetics
- Diabetes Treatment - The Number One Diabetes Exercise
- Can Exercise Alone Control Blood Sugar Level For Diabetes Type 2?
- Keep Your Blood Sugar Levels Normal - 3 Successful Tips
- Can People Suffering From Diabetes Consume the Acai Berry?
- Type 1 Diabetes Diet Foods Can Help You
- List of Foods For Diabetics to Eat - Know What's Right For You
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.